GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
GT Biopharma announces positive preclinical data for GTB-5550 in prostate cancer. The TriKE molecule demonstrated improved tumor control and NK cell cytotoxicity, even in resistant lines and hypoxia. The findings support the TriKE technology and its potential in prostate cancer treatment.
11/06/2023 - 09:30 AM
BRISBANE, CALIFORNIA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced positive preclinical data in highlighting GTB-5550’s potential in prostate cancer. Martin Felices, PhD, Associate Professor of Medicine at the University of Minnesota, presented these data on Saturday, November 4th at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, which is being held in San Diego, California November 1-5.
Natural killer (NK) cells are being increasingly explored in clinical trials due to their safety profile and ability to mediate tumor killing without prior priming. However, lack of antigen-specific targeting, decreased numbers, and suppressive signals from the tumor microenvironment (TME) of Prostate Cancer (PCa), can negatively impact NK cell efficacy. GTB-5550 was specifically designed as a novel tri-specific killer engager (TriKE® ) molecule with three components: an arm that engages with CD16, an activating receptor of NK cells, an arm that binds to tumor antigens expressed in prostate cancer (PSMA or B7H3), and an interleukin (IL)-15 moiety that is essential for NK cell survival, proliferation, priming and motility.
“These preclinical findings provide additional support for our TriKE technology and the specific mechanism of action for this construct in promoting NK-specific proliferation, effective killing of target cells and ability to bypass the myeloid-derived suppressor cells (MDSC)-induced suppression of NK cells,” stated Dr. Jeffrey Miller*, MD, GT Biopharma’s Consulting Chief Medical Officer and Consulting Chief Scientific Officer. “All of this bodes well as we progress this specific TriKE towards the clinic with the goal of an eventual indication in prostate cancer.”
Key findings demonstrated that normal donor and prostate cancer patient NK cells displayed better, specific, degranulation against prostate cancer cell lines in the presence of PSMA or B7H3 TriKEs. NK cell cytotoxicity was also improved, even in the presence of enzalutamide resistant lines, hypoxia, or MDSCs. The TriKE molecules displayed improved tumor control, compared to IL-15 control or no treatment, in xenogeneic models of prostate cancer.
Society For Immunotherapy of Cancer (SITC) 2023 Annual Meeting – November 1-5, 2023
Poster Title: Maximizing NK Cell Immunotherapy in Prostate Cancer vis TriKEs Abstract: 1180 Date: Saturday, November 4, 2023 Time: 2:55 pm -4:25 pm & 10:00 pm - 11:30 pm ET Presenter: Martin Felices*, PhD, Associate Professor of Medicine, University of Minnesota
*Drs Jeff Miller (consultant CMO) and Martin Felices are consultants for GT Biopharma and hold equity.
About GT Biopharma, Inc.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE® NK cell engager platform. Our TriKE® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE® technology. For more information, please visit gtbiopharma.com .
Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" regarding future events and our future results. All statements other than statements of historical facts are statements that could be deemed to be forward-looking statements. These statements are based on current expectations, estimates, forecasts, and projections about the markets in which we operate and the beliefs and assumptions of our management. Words such as "expects," "anticipates," "targets," "goals," "projects", "intends," "plans," "believes," "seeks," "estimates," "endeavors," "strives," "may," or variations of such words, and similar expressions are intended to identify such forward-looking statements. Readers are cautioned that these forward-looking statements are subject to a number of risks, uncertainties and assumptions that are difficult to predict, estimate or verify. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Such risks and uncertainties include those factors described in our most recent annual report on Form 10-K, as such may be amended or supplemented by subsequent quarterly reports on Form 10-Q, or other reports filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made only as of the date hereof, and we undertake no obligation to publicly release the result of any revisions to these forward-looking statements. For more information, please refer to our filings with the Securities and Exchange Commission.
TriKE®
Investor Relations Contact: LifeSci Advisors cdavis@lifesciadvisors.com
What did GT Biopharma announce?
GT Biopharma announced positive preclinical data for GTB-5550 in prostate cancer.
What is the TriKE platform?
The TriKE platform is GT Biopharma's proprietary natural killer (NK) cell engager.
What were the key findings of the preclinical data?
The key findings showed that GTB-5550 improved NK cell cytotoxicity and tumor control in prostate cancer, even in resistant lines and hypoxia.
Who presented the data?
Martin Felices, PhD, Associate Professor of Medicine at the University of Minnesota, presented the data.
When and where was the data presented?
The data was presented on Saturday, November 4th at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023 in San Diego, California.
What is the goal for GTB-5550 in prostate cancer?
The goal is to progress GTB-5550 towards the clinic with the eventual indication in prostate cancer.
